Please enable JS

Blue Companion

BLUE COMPANION provides digital services for health through private-public partnership projects. They also offer CRO services by designing and conducting clinical studies, as well as providing project management and study management services. Their privileged therapeutic domains are neurodegenerative and neuromuscular diseases, as well as ophthalmology.

 

BLUECompanion also designs, deploys and manages customised integrated ICT platforms to treat and monitor on quasi real time different data sources (auto-evaluation questionnaires, wearable devices, robotic interfaces, mobile phones…).

 

Learn more: www.bluecompanion.eu

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

Standards in Sync: Accelerating Medical Research – EUCROF Webinar

June 27, 2024

25 September 2024 from 4:00PM to 5:30PM (CEST) Webinar Overview It has been demonstrated that using standards from the start of clinical research studies (i.e. protocol and CRF development) can save significant time and resources and results in higher quality research. Unfortunately, it is not always clear how to select the appropriate standards for the […]

READ MORE
telemedecine technologies news

Addressing Data Management Challenges With Automation

June 27, 2024

Applied Clinical Trials Online ACT: How can data management challenges be addressed? Specifically, is there any opportunity to address them with artificial intelligence (AI)? Lacroix: There is a lot of opportunity across the life cycle to assist with this and it’s interesting because historically it was always: we want to throw people at some of […]

READ MORE
telemedecine technologies news

Why early market access planning is crucial in CGT commercial strategy

June 27, 2024

Fiercebiotech Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years prior to launch. This strategy should focus on addressing the nuanced market access challenges for such treatments, including but not limited to, distribution network design, tailored commercial site engagement, […]

READ MORE